Showing results (61-70 of 122) with videos related to

Sort By:
Pageof 13
World Journal of Urology|May 30, 2024
Pulmonary lesion after surgery for renal cancer: progression or new primary?Daniele Cignoli, Alessandro Bandiera, Giuseppe Rosiello, et al.
Urologic Oncology|June 6, 2022
Multidisciplinary team referral at diagnosis for patients with non-metastatic renal cell carcinomaAlberto Martini, Giuseppe Fallara, Antony A Pellegrino, et al.
Cancers|February 17, 2019
Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal AntibodiesMaria Silvia Cona, Mara Lecchi, Sara Cresta, et al.
Urologic Oncology|June 6, 2022
Clinical, pathological and long-term oncologic outcomes of papillary type I vs. type II renal cell carcinomaGiuseppe Basile, Giuseppe Rosiello, Alessandro Larcher, et al.
Clinical Genitourinary Cancer|January 8, 2014
Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancerAndrea Necchi, Luigi Mariani, Patrizia Giannatempo, et al.
The Journal of Urology|October 2, 2017
Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume CenterNicola Nicolai, Nicholas Tarabelloni, Francesca Gasperoni, et al.
Tumori|June 6, 2015
Quality of life and pain control following laparoscopic retroperitoneal lymph node dissection in early-stage nonseminomaNicola Nicolai, Elisabetta Bianchi, Ilaria Donati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2022
Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 TrialGiuseppe Basile, Marco Bandini, Ewan A Gibb, et al.
European Urology|March 31, 2021
Molecular Characterization of Residual Bladder Cancer after Neoadjuvant PembrolizumabAndrea Necchi, Joep J de Jong, Daniele Raggi, et al.
Urologic Oncology|February 10, 2022
Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinomaGiuseppe Rosiello, Alessandro Larcher, Giuseppe Fallara, et al.
Pageof 13